{"id":"remifentanil-lidoca-ne","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Muscle rigidity"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Local injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Remifentanil acts as a mu-opioid receptor agonist in the central nervous system, producing rapid-onset analgesia and sedation suitable for perioperative use. Lidocaine blocks voltage-gated sodium channels in nerve fibers, preventing action potential propagation and providing local anesthetic effects. The combination is used to provide both systemic analgesia and local anesthetic benefit during procedures.","oneSentence":"Remifentanil is a potent opioid agonist that provides analgesia and sedation, while lidocaine is a local anesthetic that blocks sodium channels to provide local pain relief.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:50.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Perioperative analgesia and sedation during surgical procedures"},{"name":"Local anesthetic adjunct in anesthesia protocols"}]},"trialDetails":[{"nctId":"NCT02597699","phase":"PHASE3","title":"Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-12-18","conditions":"Termination of Pregnancy, Feticide","enrollment":66},{"nctId":"NCT05004519","phase":"NA","title":"Benefits of Opioid Free Anesthesia on Morphine Consumption in Gastric Bypass","status":"COMPLETED","sponsor":"matthieu clanet","startDate":"2021-10-05","conditions":"Analgesics, Opioid","enrollment":183},{"nctId":"NCT01026129","phase":"NA","title":"Efficacy of Remifentanil Compared to Lidocaine on the Incidence of Coughing During Emergence of Anesthesia","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2010-04","conditions":"Cough, Anesthesia, Extubation","enrollment":93}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":249,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ultiva® + Xylocaïne®"],"phase":"phase_3","status":"active","brandName":"Remifentanil + Lidocaïne","genericName":"Remifentanil + Lidocaïne","companyName":"University Hospital, Montpellier","companyId":"university-hospital-montpellier","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Remifentanil is a potent opioid agonist that provides analgesia and sedation, while lidocaine is a local anesthetic that blocks sodium channels to provide local pain relief. Used for Perioperative analgesia and sedation during surgical procedures, Local anesthetic adjunct in anesthesia protocols.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}